Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major capsid protein L1 (Human papillomavirus type 52) (L1)
- Target
- L1
- Molecular classification
- Other (Viral structural protein)
01
Overview
Major capsid protein L1 of Human papillomavirus type 52 forms the icosahedral outer shell of the virus. L1 self-assembles into pentamers that are arranged to make up the viral capsid, playing a key role in protecting viral genetic material and mediating the initial attachment to host cell surface receptors, facilitating entry via endocytosis. L1 is the principal target for neutralizing antibodies and is the molecular basis for current prophylactic HPV vaccines. Its high immunogenicity and structural mimicry of the native virus enable the formation of effective virus-like particles for vaccine platforms[1][2][5].
- Other names
- HPV52 L1HPV type 52 major capsid proteinHPV52 capsid protein L1
02
Mechanism of action
Elicitation of neutralizing antibody responses by vaccine-induced L1 virus-like particles
03
Biological functions
Viral capsid formationVirus entry (mediates initial attachment to host cell)Facilitates endocytosis of the viral particleImmunogenicity (basis for vaccine development)
04
Disease associations
InfectionCancer (notably cervical cancer due to HPV52 infection)
05
Safety considerations
As a vaccine antigen, generally well tolerated with low safety concerns; however, cross-protection, immunogenicity variability, and rare allergic reactions are noted in population-level studies
06
Interacting drugs
Prophylactic vaccines based on L1 virus-like particles (e.g., Gardasil, Cervarix; specific coverage varies by vaccine formulation)
Beyond the preview
Go deeper on Major capsid protein L1 (Human papillomavirus type 52) (L1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Major capsid protein L1 (Human papillomavirus type 52) (L1).